

TABLE OF CONTENTS

Chapters	Page No.
List of Figures	(i)
List of Tables	(iv)
List of Abbreviations.....	(v)
Abstract.....	(ix)
CHAPTER ONE	
1. General introduction.....	1
1.1 Organization of nervous system.....	2
1.2 Cells of central nervous system.....	2
1.2.1 Glial cells	2
1.2.1.1 Astrocytes	3
1.2.1.2 Microglia	4
1.2.1.3 Oligodendrocyte	5
1.3 Oligodendrocytes development	6
1.3.1 Origin and specification	6
1.3.2 Migration	7
1.3.3 Proliferation	8
1.3.4 Differentiation.....	10
1.4 Myelination	13
1.4.1 Myelin structure and composition	13
1.5 CNS Myelin proteins	14
1.5.1 Proteolipid protein.....	14
1.5.2 Myelin Basic Proteins	16
1.5.3 Cyclic nucleotide Phosphodiesterase	17
1.5.4 Myelin-Oligodendrocyte glycoprotein	17
1.5.6 Myelin-associated glycoprotein	18

1.5.5 Myelin -associated Oligodendrocytic basic protein.....	18
1.5.6 Minor myelin proteins.....	19
1.6 Myelin assembly	20
1.7 Myelin Function	24
1.8 Myelin Disorders	24
1.8.1Multiple Sclerosis (MS).....	25
1.8.2 The Leukodystrophies.....	26
1.8.3 Adrenoleukodystrophies (ALD)	26
1.8.4 Metachromatic leukodystrophies (MLD)	26
1.8.4 Globoid Cell leukodystrophies (GLD)	27
1.8.5 Pelizaeus-Merzbacher's disease (PMD)	27
1.8.6 Progressive multifocal leukoencephalopathy (PML).....	27
1.8.7 Other Diseases	28
1.9 Regulation of Oligodendrocyte Differentiation and Myelination	28
1.9.1 Extrinsic Signaling Mechanisms Controlling Oligodendrocyte Differentiation and Myelination	28
1.9.2 Intrinsic Control of Oligodendrocyte Differentiation and Myelination	30
1.9.2.1 Transcriptional regulation.....	30
1.9.2.2 Epigenetic regulation	33
1.10 Methyl CpG Binding Domain (MBD) Proteins.....	35
1.11 MeCP2 and Rett Syndrome.....	36
1.12 MeCP2 Structure and Function	37
1. 13 Glia and MeCP2	42
1.13.1 Astrocytes and MeCP2	43
1.13.2 Oligodendrocytes and MeCP2	46
1.13.3 Microglia and MeCP2	47
1.14 MeCP2 and Cancer.....	48

1.15 Glioma.....	49
1.16 C6 glioma as model system for Glioblastoma	50
1.17 Rationale of the Present Study.....	51
1.18 Objectives	52
CHAPTER TWO	
2. Evaluation of MeCP2 mediated regulation of myelin related gene expression and oligodendrocytes cell behaviour	53
2.1 Introduction.....	54
2.2 Materials And Methods.....	55
2.2.1 Oligodendrocytes Culture and Isolation	55
2.2.2 Immunocytochemistry	56
2.2.3. Small Interfering RNA (siRNA) Transfection.....	56
2.2.4. Plasmid transfection	56
2.2.5. Restriction digestion, end filling by klenow fragment and blunt end ligation	57
2.2.6. Plasmid transformation and isolation.....	57
2.2.7. Western Blotting	57
2.2.8. RNA Isolation and qPCR.....	58
2.2.9. Statistical analysis.....	58
2.3 Results.....	58
2.3.1. Oligodendrocytes isolation and characterization.....	58
2.3.2. MeCP2 expression in Oligodendrocytes.....	59
2.3.3. MeCP2 down regulation in oligodendrocytes induce the myelin genes, BDNF and YY1 transcript level.....	59
2.3.4. MeCP2 down regulation in oligodendrocytes induce the myelin proteins (MBP, PLP and DM-20) and BDNF proteins level.....	60
2.3.5. MeCP2 regulate the oligodendrocytes precursor cells (OPCs) migration	60
2.3.6. Plasmid isolation and confirmation	60

2.3.7. MeCP2 overexpression in oligodendrocytes.....	61
2.4 Discussion.....	61
2.5 Conclusion.....	64
CHAPTER THREE	
3. Identification of genes involved in myelination for which MeCP2 act as transcriptional repressor or activator in the developing central nervous system.....	76
3.1 Introduction.....	77
3.2 Materials And Methods.....	78
3.2.1. Oligodendrocytes culture and isolation	78
3.2.2. Isolation of genomic DNA and PCR	78
3.2.3. ChIP assay	78
3.3 Results.....	79
3.3.1. In silico analysis of CpG island in myelin genes (MBP and PLP), Primer designing and optimization.....	79
3.3.2. MeCP2 bind to promoter regions of MBP and PLP genes in Oligodendrocytes	79
3.3.3. MeCP2 also bind to BDNF promoter in Oligodendrocytes	80
3.4 Discussion.....	80
3.5 Conclusion.....	81
CHAPTER FOUR	
4. Evaluation of MeCP2 function in the regulation of glioma growth and gene expression	89
4.1 Introduction.....	90
4.2 Materials And Methods.....	91
4.2.1. Cell Culture	91
4.2.2. MeCP2 Overexpression	91
4.2.3. Small Interfering RNA (siRNA) Transfection	91
4.2.4. BrdU staining assay	91

4.2.5. Scratch assay	92
4.2.6. Soft agar assay	92
4.2.7. Sphere formation assay	92
4.2.8. Adhesion assay	92
4.2.9 Invasion assay	93
4.2.10. Western blotting	93
4.2.11. RNA isolation and qPCR.....	94
4.2.12. Chromatin Immunoprecipitation (ChIP) Assay	94
4.2.13. Statistical analysis	94
4.3 Results.....	95
4.3.1. MeCP2 expression in C6 glioma	95
4.3.2. MeCP2 over expression in C6 glioma	95
4.3.3. MeCP2 impairs C6 glioma proliferation, anchorage independent growth, adhesion and sphere forming ability	95
4.3.4. MeCP2 inhibits the migration and invasion ability of C6 glioma....	96
4.3.5. MeCP2 inhibit the extracellular signal regulated kinase (ERK) signaling in C6 glioma.....	96
4.3.6. MeCP2 regulates the expression of GFAP, FAK and BDNF in C6 glioma	96
4.3.7. MeCP2 directly bind to GFAP and BDNF promoter	97
4.3.8. MeCP2 knock down in C6 glioma	97
4.3.9. MeCP2 regulates myelin gene expression differentially in C6 glioma and Oligodendrocyte	97
4.4. Discussion.....	98
4.5. Conclusion.....	100
CHAPTER FIVE	
5. Summary.....	121
Bibliography.....	125
Publications.....	166